Literature DB >> 18643758

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan.

Takeji Umemura1, Eiji Tanaka, Kendo Kiyosawa, Hiromitsu Kumada.   

Abstract

Hepatitis B virus (HBV) reactivation in patients with resolved HBV infection was found in 23 (4%) of 552 newly hepatitis B surface antigen-positive patients in Japan. Because one-fourth of cases develop into fulminant hepatic failure and mortality is 100%, management of HBV reactivation in patients with resolved HBV infection should be discussed.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18643758     DOI： 10.1086/590968

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  43 in total

Review 1.  Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.

Authors:  Shigeru Kusumoto; Yasuhito Tanaka; Ryuzo Ueda; Masashi Mizokami
Journal:  J Gastroenterol       Date:  2010-10-06       Impact factor: 7.527

2.  Still disease and the liver-an underappreciated association.

Authors:  Kieron B L Lim; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-12

3.  Reactivation of resolved hepatitis B virus infection with immune escape mutations after long-term corticosteroid therapy.

Authors:  Jun Inoue; Yasuteru Kondo; Yuta Wakui; Takayuki Kogure; Tatsuki Morosawa; Yasuyuki Fujisaka; Teruyuki Umetsu; Satoshi Takai; Takuya Nakamura; Tooru Shimosegawa
Journal:  Clin J Gastroenterol       Date:  2016-02-26

4.  Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.

Authors:  Toshihiko Ando; Kensuke Kojima; Hiroshi Isoda; Yuichiro Eguchi; Takashi Honda; Masatoshi Ishigami; Shinya Kimura
Journal:  Int J Hematol       Date:  2015-04-05       Impact factor: 2.490

5.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

6.  Serum fibronectin levels in acute and chronic viral hepatitis patients.

Authors:  Ayse Erturk; Erkan Cure; Zulal Ozkurt; Emine Parlak; Medine Cumhur Cure
Journal:  Malays J Med Sci       Date:  2014-01

7.  Two distinct subtypes of hepatitis B virus-related acute liver failure are separable by quantitative serum immunoglobulin M anti-hepatitis B core antibody and hepatitis B virus DNA levels.

Authors:  Doan Y Dao; Linda S Hynan; He-Jun Yuan; Corron Sanders; Jody Balko; Nahid Attar; Anna S F Lok; R Ann Word; William M Lee
Journal:  Hepatology       Date:  2012-01-31       Impact factor: 17.425

8.  A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?

Authors:  Kazuhiko Hayashi; Masatoshi Ishigami; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Daisaku Nishimura; Hidemi Goto; Yoshiki Hirooka
Journal:  Clin J Gastroenterol       Date:  2016-06-21

Review 9.  Reactivation of occult hepatitis B virus infection in patients with rheumatic diseases: pathogenesis, risk assessment and prevention.

Authors:  Masaru Kato; Tatsuya Atsumi
Journal:  Rheumatol Int       Date:  2015-11-16       Impact factor: 2.631

10.  Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody.

Authors:  Akihiro Matsumoto; Masayasu Imaizumi; Yasuhito Tanaka; Shuhei Nishiguchi; Hiroshi Yatsuhashi; Takehiko Ishida; Kazushige Moriyama; Katsumi Aoyagi; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2016-07-26       Impact factor: 7.527
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.